Core Insights - Melissa Astroenetica has become the second pharmaceutical company to join President Trump's most favored nation drug price program, following the establishment of a $4.5 billion plant in Virginia [1] - The agreement with Fizer, which includes a $70 billion investment in the US and lower drug prices for Medicaid, was reached just 10 days prior, allowing Fizer to avoid tariffs for three years [2] - The goal of the administration is to align 95% of US drug prices with those in Europe, indicating ongoing negotiations with various firms [3] Company Developments - The specifics of the agreement with Astroenetica are not yet clear, but it is part of a broader strategy that includes negotiations with Medicare [4] - The CMS administrator has indicated that aggressive negotiations are ongoing, with the next round of IRA price negotiations expected next month [5]